Nova Eye Medical (ASX:EYE) EBIT: A$-9.19 Mil (TTM As of Dec. 2025)


ASX:EYE Nova Eye Medical Ltd ASX:EYE
55 GF Score
Price A$0.11
GF Value A$0.18
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Nova Eye Medical EBIT?

Nova Eye Medical ASX:EYE +2.44% 55 EBIT is A$-9.19 Mil as of Dec. 2025. GuruFocus rates ASX:EYE with a GF Score™ of 55/100 and a GF Value™ of A$0.18 (Possible Value Trap). The stock has 4 warning signs investors should review.

Nova Eye Medical's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was A$-3.30 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-9.19 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Nova Eye Medical's annualized ROC % for the quarter that ended in Dec. 2025 was -48.85%. Nova Eye Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -67.79%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Nova Eye Medical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -31.29%.

Nova Eye Medical  (ASX:EYE) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Nova Eye Medical's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-9.174 * ( 1 - 0% )/( (19.096 + 18.467)/ 2 )
=-9.174/18.7815
=-48.85 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=26.504 - 2.353 - ( 5.055 - max(0, 5.154 - 12.326+5.055))
=19.096

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=23.673 - 2.583 - ( 2.623 - max(0, 5.703 - 10.554+2.623))
=18.467

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Nova Eye Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-6.592/( ( (7.249 + max(2.671, 0)) + (6.654 + max(2.874, 0)) )/ 2 )
=-6.592/( ( 9.92 + 9.528 )/ 2 )
=-6.592/9.724
=-67.79 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(4.105 + 2.814 + 0.272) - (2.353 + 0 + 2.167)
=2.671

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(4.096 + 3.499 + 0.336) - (2.583 + 0 + 2.474)
=2.874

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Nova Eye Medical's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-9.191/29.369
=-31.29 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nova Eye Medical EBIT Related Terms

Nova Eye Medical EBIT Historical Data

* Premium members only.

The historical data trend for Nova Eye Medical's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nova Eye Medical EBIT Chart

Nova Eye Medical Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.25 -9.70 -11.99 -8.97 -11.25

Nova Eye Medical Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.61 -3.36 -5.35 -5.90 -3.30

ASX:EYE vs ABT, SYK, MDT: EBIT Comparison

For the Medical Devices subindustry, Nova Eye Medical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nova Eye Medical EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nova Eye Medical's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Nova Eye Medical's EV-to-EBIT falls into.


ASX:EYE
55GF Score
Nova Eye Medical Ltd ASX:EYE
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nova Eye Medical EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-9.19 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of A$-9.19 Mil mean?
Nova Eye Medical (ASX:EYE) has a EBIT of A$-9.19 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Nova Eye Medical.
Is Nova Eye Medical's EBIT too high?
Nova Eye Medical's current EBIT is A$-9.19 Mil. Overall, Nova Eye Medical has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nova Eye Medical's EBIT compare to ABT and SYK?
Nova Eye Medical's EBIT of A$-9.19 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Nova Eye Medical. Nova Eye Medical's current EBIT is A$-9.19 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nova Eye Medical stock overvalued right now?
Based on GuruFocus' analysis, Nova Eye Medical (ASX:EYE) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.18, compared to a current price of A$0.11 — trading 41.7% below its estimated fair value. The current EBIT is A$-9.19 Mil. Nova Eye Medical's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Nova Eye Medical (ASX:EYE), the current EBIT is A$-9.19 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nova Eye Medical (ASX:EYE) Overvalued in 2026?

Based on GuruFocus' analysis, Nova Eye Medical stock appears to be undervalued. The current stock price of A$0.11 is trading 41.7% below its estimated GF Value™ of A$0.18. GuruFocus considers Nova Eye Medical to be Possible Value Trap.

Key valuation signals for ASX:EYE:

  • EBIT: A$-9.19 Mil
  • GF Value™: A$0.18 vs. price of A$0.11 (41.7% below fair value)
  • GF Score™: 55/100 with 4 warning signs

No single metric tells the full story. See the ASX:EYE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nova Eye Medical Business Description

Address 107 Rundle Street, Kent Town, Adelaide, SA, AUS, 5067
Nova Eye Medical Ltd develops and sells surgical devices for the treatment of glaucoma, a cause of blindness. In addition, the company is involved in the commercialisation of the subthreshold nano-pulse ophthalmic laser, 2RT, for the treatment of retinal disease via the AlphaRET segment. The company's reportable segments are: Glaucoma Surgical Devices and AlphaRET. The majority of its revenue is generated from the Glaucoma Surgical Devices segment, which is involved in the design, manufacture, marketing, and sale of the iTrack, iTrack Advance, and the Molteno3 glaucoma surgical device. These are all single-use surgical devices. Geographically, the company generates maximum revenue from the United States of America, followed by Europe, the Asia Pacific, Other regions, and Australia.
55GF Score

Get the complete analysis for ASX:EYE

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.11
Price
A$0.18
GF Value